The genetics a semaglutide program leaves unread A prescription does not capture the genetic architecture a GLP-1 compound acts within
Track objective and subjective markers from baseline
Differential expression analysis of different groups was performed using the DESeq2
doi:10.2337/dc22-1148 Dore DD, Seeger JD, Chan KA
Metformin is commonly used off-label in this population, and adding tirzepatide (marketed as Zepbound for weight management in non-diabetic patients) can address both the insulin resistance and the excess weight that drives it
When combined with hyaluronic acid, the results were even more significant surpassing either treatment used alone.[5] While human joint trials are still lacking, this is a promising area of investigation, particularly for patients dealing with both excess weight and degenerative joint conditions